Meeting of the Uniform Formulary Beneficiary Advisory Panel, 50049 [2013-19927]

Download as PDF Federal Register / Vol. 78, No. 159 / Friday, August 16, 2013 / Notices Microwave Radio Systems, spare and repair parts, support equipment, publications and technical data, personnel training and training equipment, site surveys, U.S. Government and contractor technical assistance, and other related elements of program and logistics support. The estimated cost is $339 million. This proposed sale will contribute to the foreign policy and national security of the United States by improving the Iraqi military’s situational awareness and enhancing command and control from its National Military Headquarters to major subordinate commands. The Government of Iraq intends to use these defense articles and services to provide critical redundancy for national level command and control. This proposed sale of this equipment and support will not alter the basic military balance in the region. The principal contractor will be Raytheon Company of Arlington, Virginia. There are no known offset agreements proposed in connection with this potential sale. Implementation of this proposed sale will require U.S. Government and contractor representatives to travel to Iraq on an as-needed basis to provide program and technical support and training. There will be no adverse impact on U.S. defense readiness as a result of this proposed sale. [FR Doc. 2013–19976 Filed 8–15–13; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Office of the Secretary Meeting of the Uniform Formulary Beneficiary Advisory Panel Assistant Secretary of Defense (Health Affairs), DoD. ACTION: Notice of meeting. AGENCY: Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., as amended, 41 CFR 102–3.150) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense (DoD) announces the following Federal advisory committee meeting of the Uniform Formulary Beneficiary Advisory Panel (‘‘the Panel’’). DATES: Thursday, September 19, 2013, from 9:00 a.m. to 1:00 p.m. ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform emcdonald on DSK67QTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 19:06 Aug 15, 2013 Jkt 229001 Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, Building 1000, San Antonio, TX 78234–6012. Telephone: (210) 295–1271 Fax: (210) 295–2789. Email Address: Baprequests@tma.osd.mil. SUPPLEMENTARY INFORMATION: Purpose of Meeting: The Panel will review and comment on recommendations made to the Director of TRICARE Management Activity, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. Meeting Agenda: 1. Sign-In 2. Welcome and Opening Remarks 3. Public Citizen Comments 4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item) a. Corticosteroids-Immune Modulators b. Self-Monitoring Blood Glucose Systems c. Renin-Angiotensin Antihypertensives d. Pulmonary-1 Agents e. Designated Newly Approved Drugs in Already-Reviewed Classes f. Pertinent Utilization Management Issues 5. Panel Discussions and Vote Meeting Accessibility: Pursuant to 5 U.S.C. 552b and 41 CFR 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. Administrative Session: Prior to the public meeting, the Panel will conduct an Administrative Session from 7:30 a.m. to 9:00 a.m. to discuss administrative matters of the Panel. The Administrative Session will be held at the Naval Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102– 3.160, the Administrative Session will be closed to the public. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140 and 10(a)(3) of the Federal Advisory Committee Act, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained from the General Services Administration’s Federal Advisory Committee Act Database at https://www.fido.gov/facadatabase/ public.asp as well as in the FOR FURTHER INFORMATION CONTACT section. PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 50049 Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will submit all written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register the day of the meeting to address the Panel. The Panel’s DFO will have a ‘‘Sign-Up Roster’’ available at the Panel meeting for registration on a first-come, firstserve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1 hour time period, no further public comments will be accepted. Anyone who signs-up to address the Panel, but is unable to do so due to the time limitation, may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel’s deliberation. To ensure timeliness of comments for the official record, the Panel encourages that individuals and interested groups consider submitting written statements instead of addressing the Panel. Dated: August 13, 2013. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2013–19927 Filed 8–15–13; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Department of the Army Draft Programmatic Environmental Impact Statement for Activities and Operations at Yuma Proving Ground, Arizona Department of the Army, DoD. Notice of Availability. AGENCY: ACTION: The Department of the Army announces the availability of the Draft Programmatic Environmental Impact Statement (DPEIS) for implementation of activities and operations at Yuma Proving Ground (YPG). This document SUMMARY: E:\FR\FM\16AUN1.SGM 16AUN1

Agencies

[Federal Register Volume 78, Number 159 (Friday, August 16, 2013)]
[Notices]
[Page 50049]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19927]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., as amended, 41 CFR 102-3.150) and the Government in the 
Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of 
Defense (DoD) announces the following Federal advisory committee 
meeting of the Uniform Formulary Beneficiary Advisory Panel (``the 
Panel'').

DATES: Thursday, September 19, 2013, from 9:00 a.m. to 1:00 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, 
Building 1000, San Antonio, TX 78234-6012. Telephone: (210) 295-1271 
Fax: (210) 295-2789. Email Address: Baprequests@tma.osd.mil.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.
Meeting Agenda:
    1. Sign-In
    2. Welcome and Opening Remarks
    3. Public Citizen Comments
    4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Corticosteroids-Immune Modulators
    b. Self-Monitoring Blood Glucose Systems
    c. Renin-Angiotensin Anti-hypertensives
    d. Pulmonary-1 Agents
    e. Designated Newly Approved Drugs in Already-Reviewed Classes
    f. Pertinent Utilization Management Issues
    5. Panel Discussions and Vote
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b and 41 CFR 102-
3.140 through 102-3.165, and the availability of space, this meeting is 
open to the public. Seating is limited and will be provided only to the 
first 220 people signing-in. All persons must sign-in legibly.
    Administrative Session: Prior to the public meeting, the Panel will 
conduct an Administrative Session from 7:30 a.m. to 9:00 a.m. to 
discuss administrative matters of the Panel. The Administrative Session 
will be held at the Naval Heritage Center, 701 Pennsylvania Avenue NW., 
Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the Administrative 
Session will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140 
and 10(a)(3) of the Federal Advisory Committee Act, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at https://www.fido.gov/facadatabase/public.asp as well as in the FOR FURTHER INFORMATION CONTACT section.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The DFO will submit all written statements 
and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register the day of the meeting to address 
the Panel. The Panel's DFO will have a ``Sign-Up Roster'' available at 
the Panel meeting for registration on a first-come, first-serve basis. 
Those wishing to address the Panel will be given no more than 5 minutes 
to present their comments, and at the end of the 1 hour time period, no 
further public comments will be accepted. Anyone who signs-up to 
address the Panel, but is unable to do so due to the time limitation, 
may submit their comments in writing; however, they must understand 
that their written comments may not be reviewed prior to the Panel's 
deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: August 13, 2013.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2013-19927 Filed 8-15-13; 8:45 am]
BILLING CODE 5001-06-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.